Wockhardt
WOCKPHARMA
Wockhardt Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 21,995 |
| Weekly | 8.37% | 11,60,373 |
| Monthly | 26.59% | 1,77,51,332 |
Wockhardt Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| WOCKPHARMA | - | 8.37% | 26.59% |
| Index | - | - | - |
| Peer Avg. | - | 5.43% | 11.51% |
Wockhardt Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| WOCKPHARMA | 6.12 | 1.36 | 20.63 | -7.60 | 0.29 | - |
| Index | 36.20 | 6.77 | 17.25 | 17.89 | 19.69 | 1.20 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Wockhardt Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 29.14% | 35.17% | -7.60% | 0.29% |
| FY '20-21 | 3.05% | -67.83% | -20.38% | -9.70% |
| FY '19-20 | -31.55% | -14.11% | -17.70% | -4.96% |
Wockhardt Shareholding Pattern
Wockhardt Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 2,301 | 2,041 | 289 | -209.50 |
| FY '20-21 | 1,847.50 | 1,948 | -14 | -344.50 |
| FY '19-20 | 1,867.03 | 1,906.12 | 33.86 | -231.81 |
Wockhardt Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| WOCKPHARMA | 2,301 | 2,041 | 289 | -209.50 |
| DBREALTY | 111.64 | 279.18 | -116.62 | -26.68 |
| DBL | 9,286.29 | 8,523.13 | 799.36 | -317.82 |
Wockhardt Share Price
Wockhardt Limited is a pharmaceutical and biotechnology company. The company's field of activity is the production and distribution of pharmaceutical and biopharmaceutical preparations, active ingredients (API) and vaccines. It produces a variety of dosage forms, including sterile injectable and lyophilized products. The company offers products in the treatment areas of dermatology, cosmetology, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough treatment and diabetology. The company's products across India are Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE, Emrok O , Emrok , FOSCHEK -S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has production and research facilities in India, the United States and the United Kingdom, and a manufacturing facility in Ireland.